Phathom Pharmaceuticals

Focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders

Phathom is a Frazier-founded company focused on developing novel therapeutics for the treatment of gastrointestinal acid-related disorders. The company has licensed rights from Takeda to develop and commercialize vonoprazan, a novel potassium-competitive acid blocker (P-CAB), in the United States, Canada, and Europe. Phathom is led by co-founders and Frazier Venture Partners David Socks and Tachi Yamada.

IPO in 2019 (NASDAQ: PHAT)
Year of Investment
Life Sciences
Chicago, Illinois